NY-ESTÉE-LAUDER
25.6.2020 14:02:08 CEST | Business Wire | Press release
This week, The Estée Lauder Companies (NYSE:EL) announced that Jane Hertzmark Hudis has been promoted to Executive Group President, effective July 1, 2020. She will continue to report directly to Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies (ELC), with brand portfolio oversight of Estée Lauder, La Mer, Bobbi Brown, AERIN, Origins, Aveda, Bumble and bumble, Dr. Jart+ and Do The Right Thing.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005430/en/
As one of the most accomplished, visionary executives in the prestige beauty industry, Jane is highly regarded for her track record of building and leading global brands. In her elevated role, Jane’s portfolio reflects several of the highest growth areas of the Company, including skin care and driving success across China and APAC, as well as with Chinese consumers around the world.
“This well-deserved promotion recognizes Jane’s exceptional leadership across the Company,” said Mr. Freda. “Throughout her career, she has made a significant impact driving brand-building expertise, spearheading the elevation of marketing and talent, and leading her portfolio of brands to achieve outstanding broad-based growth across categories, regions and channels. I am grateful to Jane for all that she has done to drive the Company’s success and as an advisor to me, and I know that she will continue to lead and inspire us to even greater heights in the future.”
As an enterprise-wide leader, most recently as Group President, Jane has been the Company’s top skin care strategist, helping to drive expertise in this critical area. Today, Estée Lauder is the number one brand in skin care globally, and La Mer is the number one brand in luxury skin care globally. A champion of the Company’s hero franchise strategy, she has driven innovation and built iconic franchises including Estée Lauder’s Advanced Night Repair and La Mer’s Créme de La Mer. The outstanding results of her brands are a testament to her strategic vision, expertise in local relevance, exceptional talent for driving innovation in product and consumer marketing, and digital communication.
A passionate advocate of leadership development and inclusion and diversity throughout her career, Jane co-founded ELC’s Women’s Leadership Network in 2017 to inspire and engage women across the organization, helping them become exceptional leaders and mentors. In partnership with co-executive sponsors Tracey T. Travis, Executive Vice President and Chief Financial Officer and Sara E. Moss, Vice Chairman, Jane has expanded the Women’s Leadership Network to over 2,000 members globally, with local chapters in France and the United Kingdom.
Jane’s expertise has been widely recognized by many best-in-class organizations. She serves on the Board of Tiffany & Co. and as a Director of the Fashion Institute of Technology (FIT) Foundation, as well as on the Advisory Board of the Breast Cancer Research Foundation.
Prior to her promotion to Group President in 2016, Jane served for seven years as Global Brand President, Estée Lauder, where she led the brand’s modernization and digital evolution to attract a new generation of global consumers. She solidified Estée Lauder's position as a global leader in high-performance prestige skin care and makeup, growing net sales by more than 40 percent and establishing it as the number one brand in its prestige distribution in Asia. Preceding her leadership of Estée Lauder, Jane served in a number of key leadership roles at the Company, including President of Origins and BeautyBank, a brand innovation think tank she founded in 2003.
About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc.
is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.
ELC-C
ELC-B
ELC-L
View source version on businesswire.com: https://www.businesswire.com/news/home/20200625005430/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
